Ian Friedland, MD

Ian Friedland, MD, is the VP of Clinical Research at Cubist Pharmaceuticals, Inc., responsible for clinical development of the anti-infective franchise. Prior to joining Cubist in 2009, he became a compound development team leader at Johnson and Johnson Pharmaceuticals and a senior director at Peninsula Pharmaceuticals, Inc after joining the pharmaceutical industry with Merck. Dr. Friedland earned his MD at the University of the Witwatersrand in Johannesburg, South Africa, and completed his pediatric residency at the Montefiore Medical Center in New York and his infectious disease fellowship at the University of Texas Southwestern Medical Center in Dallas. Dr. Friedland is a pediatric infectious disease specialist with more than 12 years’ industry experience.